[{"id":"0dd3a28d-1be7-40ff-a066-40868ec0b07e","acronym":"KG 4/2015","url":"https://clinicaltrials.gov/study/NCT02854072","created_at":"2021-01-18T14:00:33.938Z","updated_at":"2024-07-02T16:37:27.514Z","phase":"Phase 3","brief_title":"A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients","source_id_and_acronym":"NCT02854072 - KG 4/2015","lead_sponsor":"Samsung Pharmaceutical Co., Ltd.","biomarkers":" CCL11 • CA 19-9","pipe":"","alterations":" ","tags":["CCL11 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • LucaVax (tertomotide)"],"overall_status":"Unknown status","enrollment":" Enrollment 148","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2016-11-22"}]